

Pre-close brief Q3 2025

Gothenburg, Sweden, September 5, 2025


In line with the ESMA guidelines, we no longer have pre-close calls. The purpose of this pre-close brief is to provide a summary of links and information as support to the public ahead of the next quarterly report.

Financial target 2024-2028

- **>12% adjusted EPS CAGR:** Communicated on slide 11 in the Capital Markets Update on May 15, 2024.

Outlook

- **Short-term:**
 - **Net Sales:** Our latest outlook on net sales for 2025 was provided on page 1 in the Q2 2025 report released on July 18, 2025. Please see link to report and transcript below.
- **2024-2028:**
 - **Net Sales:** Our latest outlook on net sales for 2024-2028 was provided on slide 14 in the Capital Markets Update on May 15, 2024, see link to presentation and transcript below.
 - **EBITA margin:** Our latest outlook on EBITA margin for 2024-2028 was provided on slide 14 in the Capital Markets Update on May 15, 2024, see link to presentation and transcript below.



Getinge | Capital Market Update | May 2024
Page 14

Reports and Transcripts from earnings calls and Capital Markets Update

- Capital Markets Update (May 15, 2024)
 - [Presentation](#) / [Transcript](#)
- Q2 2025 (July 18, 2025) – for sequential trend considerations
 - [Report](#) / [Transcript](#)
- Q3 2024 (Oct 23, 2024) – for y-o-y considerations
 - [Report](#) / [Transcript](#)

Factors impacting YoY comparative figures

- **Order intake and net sales:** Read more about the order intake and net sales development on page 2 and 6-8 in the Q3 2024 report
- **Margins:** Read more about the margin development on page 3 and 6-8 in the Q3 2024 report
- **Sustainability:** Read more about the Sustainability development on page 5 in the Q2 2025 (sequentially) and Q3 2024 report (YoY)
- **Currency:** Getinge is net long USD versus SEK and EUR. I.e. in general, Getinge benefits from a stronger USD
- **Specific events and one offs:** Read more about any specific events and one offs on page 1 and 9 respectively in the notes on page 20-25 in the Q3 2024 report

Latest estimates

- [Consolidated analyst estimates \(Modular Finance\)](#)

Press releases during Q3 2025

- [Getinge news section](#)

Financial calendar

Interim Report, Q3 Jul-Sep 2025

October 21, 2025

Contact information:

Lars Mattsson, SVP Enterprise Development

Phone: +46 (0)10 335 0043

Email: lars.mattsson@getinge.com

On parental leave until September 28, 2025:

David Kördel, Head of Investor Relations

Phone: +46 (0)10 335 0077

Email: david.kordel@getinge.com

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile processing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.